Dott.ssa Viola Sanga

Specialist in endocrinology and metabolic diseases

With years of both clinical and research experience in the field of cardio-metabolic diseases, I mainly dedicate myself to the management of patients suffering from diabetes, hypertension and other metabolic diseases, such as obesity and cholesterol problems, as well as the management of thyroid diseases. I also deal with diabetes and thyroid problems during pregnancy.

2014: Degree in Medicine and Surgery at the University of Padua.

2020: Specialization in Endocrinology and Metabolic Diseases at the University of Verona (70/70 with honors).

2023: PhD (PhD) in Arterial Hypertension and Vascular Biology, achieved jointly with the Sapienza University of Rome and the University of Padua.

Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020 Apr 6;9:e57278.
Sanga V, Lenzini L, Seccia TM, Rossi GP. Familial Hyperaldosteronism Type 1 and Pregnancy: Successful Treatment with Low Dose Dexamethasone. Blood Pressure. 2021 Jan 4:1-5.
Schiavone D*, Sanga V*, Iacobone M, Rossi GP. Letter to the editor on “Ablation versus laparoscopic adrenalectomy for the treatment of aldosterone-producing adenoma: a meta-analysis”. Abdom Radiol (NY). 2021 Feb 23. (* = co-first authors)
Cignarella A, Fadini GP, Bolego C, Trevisi L, Boscaro C, Sanga V, Seccia TM, Rosato A, Rossi GP, Barton M. Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges. Cardiovasc Res. 2021 Mar 19:cvab096.
Sanga V, Seccia TM, Rossi GP. A Systematic Review of Pathophysiology and Management of Familial Hyperaldosteronism Type 1 in Pregnancy. Endocrine. 2021 May 27.
Sanga V, Rossitto G, Seccia TM, Rossi GP. Management and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review. Hypertension. 2022 Jun 10.
Shagjaa T, Sanga V, Rossi GP. Skin Hyperpigmentation Due to Post-Surgical Adrenal Insufficiency Regressed with the Dexamethasone Treatment. J Clin Med. 2022 Sep 13.